RxDoctor Payments Data

Joseph Shapiro, MD

Allergy & Immunology · Studio City, CANPI 1528070737

Payments from drug & device makers

$47,766in general payments, 2019–2025

Across 20 payments — averaging $2388.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$46K
  • Sanofi$1K
  • Amgen$124
  • Regeneron Healthcare Solutions, Inc.$96
  • Novartis$58
  • Genentech, Inc.$48
  • plus $19 from 1 others

What the payments were for

  • Consulting fees$1,09566%
  • Food & beverage$51131%
  • Education$604%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca9$46,236
Sanofi5$1,185
Amgen1$124
Regeneron Healthcare Solutions, Inc.1$96
Novartis2$58
Genentech, Inc.1$48
GSK1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,766 in reported general payments places this provider in the 85th percentile of 426 allergy & immunology providers in California.

See all allergy & immunology providers in California

Medicare billing

Part B allowed, 2024
$191,831
Medicare patients
254
Services billed
8,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5046$278,747
Trelegy ElliptaFluticasone/Umeclidin/Vilanter153$126,201
Dupixent SyringeDupilumab12$117,985
XolairOmalizumab11$111,364
Dupixent PenDupilumab11$93,533
Spiriva RespimatTiotropium Bromide56$46,757
Breo ElliptaFluticasone/Vilanterol63$32,816
XembifyImmune Globulin,gamma(Igg)klhw17$20,289
RyaltrisOlopatadine Hcl/Mometasone43$14,498
Qvar RedihalerBeclomethasone Dipropionate39$14,014
Azelastine-FluticasoneAzelastine/Fluticasone115$11,473
DuleraMometasone/Formoterol17$8,363
SymbicortBudesonide/Formoterol Fumarate21$6,061
Fluticasone Propionate HfaFluticasone Propionate12$5,417
Arnuity ElliptaFluticasone Furoate17$4,245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$19$163,262233 claims
Genentech, Inc.Xolair$48$111,36411 claims
AstraZenecaSymbicort$46,236$6,06121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 426 allergy & immunology providers in California.

Other allergy & immunology in Studio City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →